Oncology

Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

December 11, 2007

AudioMedica News

00:00 /

Anton Hagenbeek

ANTON HAGENBEEK, University Medical Centre Utrecht
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.

LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071209_anton_hagenbeek.mp3]

Tagged as:ash comments lymphoma medical medication patient podcast podcasting report reports study toxicity

AUDIO JOURNAL OF ONCOLOGY—Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis

12 months ago

A new research method has elucidated cellular processes (involving mutated TP53 oncogene) that can convert a relatively benign myeloproliferative...

Infectious Disease AJO Cardiovascular General Medicine News Oncology Primary Health Care Public Health Video

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

May 28, 2020

Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...

Audio AJO Oncology

CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second Study Confirms

February 24, 2020

Audio Journal of Oncology Podcast CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second Study Confirms Play Episode Pause Episode Mute/Unmute...

Audio AJO Oncology

Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent

February 7, 2020

Audio Journal of Oncology Podcast Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent Play Episode Pause Episode Mute/Unmute Episode...

Audio AJO Oncology

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

January 24, 2020

Audio Journal of Oncology Podcast New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia Play Episode Pause Episode Mute/Unmute...

Audio AJO Oncology

Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation

January 14, 2020

Audio Journal of Oncology Podcast Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation Play Episode Pause Episode...

Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

Further reading

AUDIO JOURNAL OF ONCOLOGY—Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second Study Confirms

Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation

Menu

Sign up for AudioMedica.com news

Live Report from ASH:Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

Further reading

AUDIO JOURNAL OF ONCOLOGY—Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second Study Confirms

Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation

Menu

Sign up for AudioMedica.com news

Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma